Navigation Links
Personalized molecular therapy shows promising results for people with advanced lung cancer
Date:12/9/2010

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

Epigenetics therapy is an approach designed to control the expression of good and bad genes that influence the development of resistance to targeted therapies. This study, called ENCORE 401, was designed to evaluate whether entinostat, a novel epigenetic therapy that is given orally, can be used to delay or overcome the resistance to erlotinib in patients with advanced lung cancer.

This study was a randomized phase II placebo controlled clinical trial in advanced lung cancer examining whether entinostat in combination with erlotinib is better than erlotinib alone and whether it can be safely tolerated by patients. As part of the clinical trial, patients underwent an analysis of various tissue and blood biomarkers. The results demonstrated that patients with elevated E-cadherin (a molecular marker) who were administered entinostat in combination with erlotinib had a significantly improved overall survival as compared to patients treated with erlotinib alone. Approximately 40 percent of non-small cell lung cancer patients have elevated E-cadherin.

These findings highlight the importance of patient selection in defining treatment approaches in lung cancer and, if confirmed, could provide benefit to patients who have or develop resistance to current molecular targeted therapy.

"The results of ENCORE 401 identified a subset of lung cancer patients for whom the combination of epigenetic therapy, entinostat and molecular targeted therapy, erlotinib, achieved promising results," Robert M. Jotte, M.D., Ph.D., principal investigator of the study, director of thoracic oncology at Rocky Mountain Cancer Center Midtown Division in Denver and developmental co-chair of US Oncology Lung Committee, said. "These results support the ongoing drive toward using personalized health care to dictate therapy in an attempt to optimize outcomes. A follow-up study to advance the combination toward registration is planned."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
2. Personalized medicine: Tumor analysis reveals new opportunities for existing cancer drugs
3. New venture explores frontiers of personalized medicine
4. Personalized treatment may help some liver cancer patients
5. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
6. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
7. Personalized medicine: Molecular imaging predicts treatment success in many cancers
8. Pilot study supports adolescent diabetes patients through personalized text messages
9. Tumor target suggests personalized treatment for melanoma
10. Advances in personalized medicine take center stage
11. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 ... ... Complying with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, ... ET, http://www.fdanews.com/mdclineval                  , How will the new EU MDR language ...
(Date:3/23/2017)... ... 23, 2017 , ... News Advisory/Interview Opportunity , After six years of advocacy, ... in Europe for public health and the environment and is calling on the United ... and the overwhelming support of European citizens, the European Union (EU) will, beginning next ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: ... with an infinitely more profound faith of God’s promise of Heaven for His people. ... who spends each day with his wife, three children and six grandchildren living and ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying and ... Scotty, a fiction writer with an active imagination and an enthusiasm for action and ... the tale of Wild Bill Hart, who sat looking at the thirty-three notches that ...
(Date:3/22/2017)... , ... March 23, 2017 , ... Death anxiety is ... by profession, author Joy Nugent was inspired to write the book titled “ As ... her inward desire to make sense of what she was experiencing at the bedside ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... , March 23, 2017 ... ended the trading session at 5,821.64, up 0.48%; ... to finish at 20,661.30; and the S&P 500 ... broad based as six out of nine sectors ... has initiated reports coverage on the following Medical ...
(Date:3/23/2017)... March 23, 2017 ... Enterprises Limited, gibt die Ernennung von Stuart ... bietet seinen globalen Pharmazeutikkunden eine einmalige integrierte ... wichtige Rolle für das erfolgreiche Wachstum und ... Leiter wird Herr Needleman dafür verantwortlich sein, ...
Breaking Medicine Technology: